# A Rollover Study to Provide Continued Treatment With Eltrombopag

> **NCT01957176** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Thrombocytopaenia

## Interventions

- **DRUG:** Eltrombopag (ELT)

## Key facts

- **NCT ID:** NCT01957176
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-15
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957176, "A Rollover Study to Provide Continued Treatment With Eltrombopag". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01957176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*